Drugs / AZD2816
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04973449 | Jun 2021 → Feb 2022 | COVID-19 | AstraZeneca | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | Results ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies astrazeneca.com ↗
Persistently high immunogenicity and between-country differences driven by hybrid immunity from primary-series AZD2816 or AZD1222 (ChAdOx1 nCoV-19) and Omicron infections |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies astrazeneca.com ↗ |
| 2021-06-27 | AstraZeneca | First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated astrazeneca.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04973449 ↗ |
| Modality | Vaccine | “AZD2816 is a variant-adapted COVID-19 vaccine” PMID 38878794 ↗ Jun 2024 |